KPRX — KIORA PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1372514 ·
Last close
$0.93
Market Cap
$4.11M
52W High
$2.91
52W Low
$0.93
ADV30
54,330
Next earnings
—
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -2,124,357 -2,079,010 23,776,090 7,076,533 6,919,401
Mar 2026 0 — -2,502,768 -2,417,984 21,227,089 10,955,359 7,292,528
Dec 2025 0 — -2,630,193 -6,516,521 24,253,300 8,696,570 8,126,764
Sep 2025 0 — -2,515,470 26,806 29,863,454 5,508,899 7,452,712

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,506,809
Investing CF
$9,601,536
Financing CF
$4,918,285
CapEx
$-107,068
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.45
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-158,714,270
Inventory
—
Receivables
$2,906,464
ST Investments
$9,761,994
EBIT TTM
$-12,410,884
Pretax Income TTM
$-12,279,808
Interest Exp TTM
—
Analysts
1

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -9,459,247 -10,835,154 24,253,300 8,126,764 16,126,536 -9,961,176
Dec 2024 16,000,000 5,580,819 3,594,733 36,484,484 10,724,708 25,759,776 8,559,115
Dec 2023 0 -8,690,183 -12,513,896 13,711,870 7,602,216 6,109,654 -9,556,951
Dec 2022 0 -11,726,918 -13,583,610 18,678,259 7,270,659 11,407,600 -10,428,133
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-10,986,709
OpCashFlow TTM
—
Assets (Latest)
$23,776,090
Forward EPS
$-2.23

Peers — same industry

TickerNameMarket CapLastDaily %
RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC. $4.02M $0.31 —
TCRT Alaunos Therapeutics, Inc. $4.22M $1.66 —
SILO Silo Pharma, Inc. $4.00M $1.71 —
XTLB XTL BIOPHARMACEUTICALS LTD $3.98M $1.62 —
IMNN Imunon, Inc. $3.97M $0.61 —

News headlines (Yahoo Finance, 1h cache)

Kiora Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-12 12:00 · Yahoo
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Tri
2026-10-29 11:00 · Yahoo
Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
2026-08-19 11:00 · Yahoo
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
2026-07-02 11:00 · Yahoo
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
2026-04-14 11:00 · Yahoo
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
2026-04-07 11:00 · Yahoo
Kiora Pharmaceuticals Announces Management Team Changes
2026-04-02 20:30 · Yahoo
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-08 11:00 · Yahoo
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
2026-09-08 11:00 · Yahoo
SS Innovations International (SSII) Appoints Sarah Romano as Chief Financial Officer
2026-07-15 18:25 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.